ATRC,BONE,CDXS,MRIC.OB,SRPT Stock Quote

ATRC [NASD]

Healthcare | Medical Instruments & Supplies | USA

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	2.00%	Shs Outstand	44.63M	Perf Week	10.28%
Market Cap	3.47B	Forward P/E	-	EPS next Y	-0.91	Insider Trans	-35.07%	Shs Float	43.51M	Perf Month	17.28%
Income	-48.70M	PEG	-	EPS next Q	-0.34	Inst Own	98.00%	Short Float	4.52%	Perf Quarter	31.86%
Sales	212.60M	P/S	16.30	EPS this Y	-22.10%	Inst Trans	0.55%	Short Ratio	4.48	Perf Half Y	120.27%
Book/sh	8.77	P/B	8.78	EPS next Y	27.20%	ROA	-6.90%	Target Price	82.71	Perf Year	87.56%
Cash/sh	5.05	P/C	15.26	EPS next 5Y	20.00%	ROE	-11.90%	52W Range	34.04 - 79.54	Perf YTD	38.37%
Dividend	-	P/FCF	-	EPS past 5Y	-3.30%	ROI	-9.30%	52W High	-3.16%	Beta	1.07
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	9.70%	Gross Margin	72.90%	52W Low	126.29%	ATR	3.20
Employees	750	Current Ratio	5.10	Sales Q/Q	11.50%	Oper. Margin	-21.00%	RSI (14)	69.87	Volatility	5.12% 4.25%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	10.70%	Profit Margin	-22.90%	Rel Volume	0.68	Prev Close	77.33
Shortable	Yes	LT Debt/Eq	0.15	Earnings	Apr 27 AMC	Payout	-	Avg Volume	439.04K	Price	77.03
Recom	1.40	SMA20	11.14%	SMA50	16.41%	SMA200	49.85%	Volume	298,317	Change	-0.39%

Dec-18-20

Reiterated

Needham

Buy

$53 → $63

Nov-06-20

Reiterated

Needham

Buy

$63 → $53

Apr-07-20

Initiated

Oppenheimer

Outperform

$45

Feb-06-20

Initiated

BTIG Research

Buy

$42

Jan-24-20

Reiterated

Needham

Buy

$39 → $48

Aug-13-19

Downgrade

Northland Capital

Outperform → Market Perform

$30

Apr-12-19

Initiated

JP Morgan

Overweight

$37

Oct-04-18

Reiterated

Needham

Buy

$36 → $39

Aug-02-18

Reiterated

Stifel

Buy

$32 → $34

Aug-02-18

Reiterated

Needham

Buy

$32 → $36

Jun-18-18

Reiterated

Needham

Buy

$26 → $32

Apr-27-18

Reiterated

Needham

Buy

$23 → $26

Jan-16-18

Reiterated

Needham

Buy

$25 → $23

Nov-02-17

Reiterated

Needham

Buy

$26 → $25

Jul-28-17

Reiterated

Needham

Buy

$25 → $26

May-30-17

Resumed

Piper Jaffray

Overweight

Jun-30-16

Resumed

JMP Securities

Mkt Outperform

Oct-28-15

Reiterated

Needham

Buy

$30 → $23

Oct-06-15

Reiterated

Needham

Buy

$32 → $30

Oct-06-15

Reiterated

Canaccord Genuity

Buy

$31 → $28

Apr-30-21 06:57AM	AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock? Zacks
02:33AM	Can You Imagine How Elated AtriCure's (NASDAQ:ATRC) Shareholders Feel About Its 427% Share Price Gain? Simply Wall St.
Apr-29-21 07:00AM	AtriCures EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients Business Wire +8.80%
Apr-28-21 11:30AM	AtriCure Inc (ATRC) Q1 2021 Earnings Call Transcript Motley Fool +7.61%
Apr-27-21 05:25PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	AtriCure Reports First Quarter 2021 Financial Results Business Wire
02:45PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Apr-08-21 08:00AM	AtriCure Names B. Kristine Johnson Board Chair Business Wire
Apr-06-21 08:00AM	AtriCure to Announce First Quarter 2021 Financial Results Business Wire
Mar-02-21 04:01PM	AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference Business Wire
Feb-24-21 03:01AM	AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript Motley Fool
Feb-23-21 04:25PM	AtriCure: Q4 Earnings Insights Benzinga
04:01PM	AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:19AM	Earnings Preview: AtriCure Benzinga
Feb-10-21 08:00AM	AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference Business Wire
Feb-02-21 08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results Business Wire
Jan-25-21 11:57PM	Have Insiders Been Buying AtriCure, Inc. (NASDAQ:ATRC) Shares This Year? Simply Wall St.
Jan-12-21 08:15AM	The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga
Jan-11-21 07:00AM	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Business Wire
Jan-04-21 08:00AM	AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy Business Wire
Dec-21-20 08:42AM	AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session Zacks
12:12AM	Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet? Simply Wall St.
Dec-19-20 04:45PM	Is ATRC A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-14-20 08:00AM	AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-04-20 12:00PM	AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know Zacks
Nov-19-20 11:44AM	Insider Buys AtriCure Stock Benzinga +5.00%
08:00AM	AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-06-20 09:30AM	AtriCure Inc (ATRC) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 06:25PM	AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	AtriCure Reports Third Quarter 2020 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 12:35PM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-26-20 08:00AM	AtriCure to Participate in Upcoming Investor Conferences Business Wire
Oct-13-20 08:00AM	AtriCure to Announce Third Quarter 2020 Financial Results Business Wire
Oct-06-20 05:41PM	Do Hedge Funds Love AtriCure Inc. (ATRC)? Insider Monkey
Sep-28-20 06:39AM	What We Learned About AtriCure's (NASDAQ:ATRC) CEO Compensation Simply Wall St.
Sep-01-20 08:00AM	AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Aug-06-20 04:00PM	AtriCure Announces Angie Wirick as Chief Financial Officer Business Wire
Aug-03-20 08:55AM	AtriCure Inc. (ATRC): Were Hedge Funds Right About Buying This Stock? Insider Monkey
Jul-30-20 06:39AM	Analysts Have Made A Financial Statement On AtriCure, Inc.'s (NASDAQ:ATRC) Second-Quarter Report Simply Wall St.
Jul-29-20 08:00AM	AtriCure to Participate at Upcoming Investor Conferences Business Wire -5.13%
05:01AM	AtriCure Inc (ATRC) Q2 2020 Earnings Call Transcript Motley Fool
Jul-28-20 04:22PM	Recap: AtriCure Q2 Earnings Benzinga
04:01PM	AtriCure Reports Second Quarter 2020 Financial Results Business Wire
Jul-21-20 12:31PM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-07-20 08:00AM	AtriCure to Announce Second Quarter 2020 Financial Results Business Wire -6.39%
Jun-19-20 12:45PM	Hedge Funds Are Buying AtriCure Inc. (ATRC) Insider Monkey
Jun-17-20 04:53AM	Edited Transcript of ATRC.OQ earnings conference call or presentation 29-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
May-11-20 08:10PM	AtriCure Announces Pricing of Public Offering of Common Stock Business Wire
07:16AM	AtriCure Announces Proposed Public Offering of Common Stock Business Wire
May-08-20 08:47AM	AtriCure Announces Results from CONVERGE IDE Clinical Trial Business Wire +7.70%
Apr-30-20 11:00AM	AtriCure Inc (ATRC) Q1 2020 Earnings Call Transcript Motley Fool
08:30AM	AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting Business Wire
Apr-29-20 05:25PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates Zacks +5.61%
04:01PM	AtriCure Reports First Quarter 2020 Financial Results Business Wire
Apr-27-20 04:02PM	AtriCure to Participate at Upcoming Investor Conferences Business Wire
Apr-22-20 12:31PM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-15-20 08:00AM	AtriCure to Announce First Quarter 2020 Financial Results Business Wire
Apr-14-20 06:42AM	Some Analysts Just Cut Their AtriCure, Inc. (NASDAQ:ATRC) Estimates Simply Wall St.
Apr-13-20 08:00AM	AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting Business Wire
Apr-09-20 12:26PM	AtriCure C-suite taking pay cuts as revenue dips because of coronavirus American City Business Journals
08:00AM	AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update Business Wire
Apr-06-20 04:14PM	Dayton stocks reap massive gains as broad market skyrockets American City Business Journals +7.52%
Apr-01-20 03:00PM	Dayton stocks dive again after Q1 registers biggest drop since 2008 American City Business Journals
Mar-24-20 05:09PM	These Dayton stocks skyrocketed as market posts best day since 1933 American City Business Journals +9.52%
Mar-23-20 02:29PM	Here's how Dayton stocks fared as Dow falls to lowest level since 2016 American City Business Journals
Mar-12-20 09:21AM	Dayton stocks tumble as Dow falls, ending 11-year bull run American City Business Journals -13.35%
Feb-28-20 02:53PM	Dayton stocks face sharp declines as equity market tumbles American City Business Journals
Feb-25-20 10:37PM	Edited Transcript of ATRC earnings conference call or presentation 18-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-20-20 05:54AM	US$49.43 - That's What Analysts Think AtriCure, Inc. Is Worth After These Results Simply Wall St.
Feb-18-20 04:01PM	AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Feb-03-20 08:00AM	AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference Business Wire
Jan-31-20 07:33AM	Is AtriCure (NASDAQ:ATRC) Using Debt Sensibly? Simply Wall St.
Jan-28-20 11:15AM	Here's how Dayton-area stocks performed in 2019 American City Business Journals
08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2019 Financial Results Business Wire
Jan-10-20 08:14AM	AtriCure Enters Overbought Territory Zacks
Jan-07-20 08:00AM	AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol Business Wire
Dec-16-19 08:00AM	AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference Business Wire
Dec-10-19 11:28AM	Why AtriCure CEO Mike Carrel wants title of heart surgeon for a day American City Business Journals
Dec-09-19 01:12PM	Did Hedge Funds Drop The Ball On AtriCure Inc. (ATRC) ? Insider Monkey
Dec-05-19 06:13AM	Medical device maker south of Dayton gets board refresh American City Business Journals
Dec-04-19 08:00AM	AtriCure Names Two Industry Veterans to Board of Directors Business Wire
Dec-02-19 09:33AM	Is AtriCure, Inc.'s (NASDAQ:ATRC) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-12-19 08:00AM	AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-06-19 02:22PM	Edited Transcript of ATRC earnings conference call or presentation 30-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-30-19 06:15PM	AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	AtriCure Reports Third Quarter 2019 Financial Results Business Wire
Oct-27-19 02:02PM	Is AtriCure Inc. (ATRC) A Good Stock To Buy ? Insider Monkey
Oct-23-19 10:33AM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-21-19 08:00AM	AtriCure to Participate in Upcoming Investor Conferences Business Wire
Oct-09-19 06:18PM	This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks Insider Monkey
Oct-08-19 11:06AM	Does AtriCure's (NASDAQ:ATRC) Share Price Gain of 64% Match Its Business Performance? Simply Wall St.
08:00AM	AtriCure to Announce Third Quarter 2019 Financial Results Business Wire
Sep-02-19 03:18PM	How AtriCure, Inc.'s (NASDAQ:ATRC) Earnings Growth Stacks Up Against The Industry Simply Wall St.
Aug-28-19 10:50AM	AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm Zacks
Aug-27-19 08:00AM	AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices Business Wire
Aug-26-19 08:00AM	AtriCure to Participate at the Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-14-19 02:26PM	The Funded: 6 Bay Area companies raise $274M at midweek American City Business Journals

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WEHRWEIN SVEN	Director	May 03	Option Exercise	19.95	5,000	99,750	17,686	May 05 07:58 AM
WEHRWEIN SVEN	Director	May 03	Sale	77.97	10,000	779,700	12,686	May 05 07:58 AM
Collar Mark A	Director	Apr 01	Sale	65.28	3,000	195,840	72,558	Apr 05 08:07 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 12	Option Exercise	21.04	25,000	526,000	529,795	Feb 12 04:30 PM
CARREL MICHAEL H	President, CEO, & Director	Feb 12	Sale	65.00	25,000	1,625,000	504,795	Feb 12 04:30 PM
CARREL MICHAEL H	President, CEO, & Director	Feb 11	Option Exercise	21.04	25,000	526,000	529,795	Feb 12 04:30 PM
CARREL MICHAEL H	President, CEO, & Director	Feb 11	Sale	64.00	25,000	1,600,000	504,795	Feb 12 04:30 PM
CARREL MICHAEL H	President, CEO, & Director	Feb 10	Option Exercise	21.04	25,000	526,000	529,795	Feb 12 04:30 PM
CARREL MICHAEL H	President, CEO, & Director	Feb 10	Sale	63.00	25,000	1,575,000	504,795	Feb 12 04:30 PM
CARREL MICHAEL H	President, CEO, & Director	Feb 09	Option Exercise	21.04	25,000	526,000	529,795	Feb 10 08:52 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 09	Sale	62.00	25,000	1,550,000	504,795	Feb 10 08:52 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 08	Option Exercise	21.04	25,000	526,000	529,795	Feb 10 08:52 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 08	Sale	61.00	25,000	1,525,000	504,795	Feb 10 08:52 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 02	Option Exercise	21.04	25,000	526,000	529,795	Feb 04 09:03 AM
Seith Douglas J	Chief Operating Officer	Feb 02	Sale	60.00	14,941	896,460	95,939	Feb 04 09:06 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 02	Sale	60.00	25,000	1,500,000	504,795	Feb 04 09:03 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 11	Option Exercise	21.04	25,000	526,000	529,795	Jan 13 04:27 PM
CARREL MICHAEL H	President, CEO, & Director	Jan 11	Sale	59.00	25,000	1,475,000	504,795	Jan 13 04:27 PM
Noznesky Justin J	SVP, Mktg & Business Develop	Jan 04	Option Exercise	18.30	15,000	274,500	66,005	Jan 06 07:45 AM
Collar Mark A	Director	Jan 04	Sale	55.36	3,000	166,080	75,558	Jan 06 07:47 AM
Noznesky Justin J	SVP, Mktg & Business Develop	Jan 04	Sale	53.58	23,397	1,253,713	42,608	Jan 06 07:45 AM
CARREL MICHAEL H	President, CEO, & Director	Dec 28	Option Exercise	21.04	24,953	525,011	529,457	Dec 28 08:09 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 28	Sale	58.00	24,953	1,447,274	504,504	Dec 28 08:09 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 23	Option Exercise	21.04	47	989	504,551	Dec 28 08:09 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 23	Sale	58.00	47	2,726	504,504	Dec 28 08:09 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 22	Option Exercise	21.04	50,000	1,052,000	529,594	Dec 23 04:23 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 22	Sale	56.50	50,000	2,825,000	504,504	Dec 23 04:23 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 21	Option Exercise	21.04	24,751	520,761	529,255	Dec 23 04:23 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 21	Sale	55.00	24,751	1,361,305	504,504	Dec 23 04:23 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 18	Option Exercise	21.04	50,249	1,057,239	554,753	Dec 21 05:07 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 18	Sale	53.51	50,249	2,688,824	504,504	Dec 21 05:07 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 17	Option Exercise	10.95	75,000	821,500	529,504	Dec 21 05:07 PM
CARREL MICHAEL H	President, CEO, & Director	Dec 17	Sale	51.00	75,000	3,825,000	504,504	Dec 21 05:07 PM
Privitera Salvatore	Chief Technical Officer	Dec 17	Sale	51.33	10,654	546,870	68,262	Dec 21 05:03 PM
Seith Douglas J	Chief Operating Officer	Dec 17	Sale	50.00	18,617	930,850	110,880	Dec 21 05:00 PM
Privitera Salvatore	Chief Technical Officer	Dec 09	Sale	47.50	3,846	182,685	78,916	Dec 11 07:52 AM
Drake Scott William	Director	Nov 17	Buy	40.54	12,350	500,669	41,036	Nov 19 07:40 AM
Seith Douglas J	Chief Operating Officer	Oct 09	Sale	40.09	29,161	1,169,064	129,497	Oct 13 08:23 AM
Collar Mark A	Director	Oct 06	Sale	40.00	2,330	93,200	78,558	Oct 08 08:39 AM
Collar Mark A	Director	Oct 01	Sale	40.20	670	26,934	80,888	Oct 05 08:45 AM
GROVES REGINA E	Director	Sep 14	Sale	41.83	6,313	264,073	21,809	Sep 16 04:12 PM
Collar Mark A	Director	Jul 01	Sale	44.60	4,000	178,400	81,558	Jul 06 08:21 AM
Collar Mark A	Director	May 12	Option Exercise	5.15	10,000	51,500	83,106	May 14 08:12 AM
CARREL MICHAEL H	President, CEO, & Director	May 12	Option Exercise	5.91	25,000	147,750	539,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 12	Sale	47.00	25,000	1,175,000	514,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 11	Option Exercise	5.91	25,000	147,750	539,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 11	Sale	46.00	25,000	1,150,000	514,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 08	Option Exercise	5.91	25,000	147,750	539,147	May 08 05:02 PM
CARREL MICHAEL H	President, CEO, & Director	May 08	Sale	45.00	25,000	1,125,000	514,147	May 08 05:02 PM

open in screener | open in yahoo | open in reuters | open in marketwatch | open in google

publish chart | save to portfolio | create alert

CDXS [NASD]

Codexis, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.41	Insider Own	0.80%	Shs Outstand	60.49M	Perf Week	-17.57%
Market Cap	1.34B	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-16.65%	Shs Float	53.09M	Perf Month	-20.03%
Income	-24.00M	PEG	-	EPS next Q	-0.20	Inst Own	96.60%	Short Float	11.80%	Perf Quarter	-27.26%
Sales	69.10M	P/S	19.36	EPS this Y	-91.60%	Inst Trans	1.95%	Short Ratio	10.21	Perf Half Y	56.98%
Book/sh	2.81	P/B	7.25	EPS next Y	-4.90%	ROA	-14.80%	Target Price	27.50	Perf Year	72.69%
Cash/sh	2.28	P/C	8.91	EPS next 5Y	15.00%	ROE	-21.10%	52W Range	10.28 - 29.56	Perf YTD	-6.73%
Dividend	-	P/FCF	-	EPS past 5Y	-16.00%	ROI	-14.30%	52W High	-31.12%	Beta	1.27
Dividend %	-	Quick Ratio	7.30	Sales past 5Y	10.60%	Gross Margin	80.10%	52W Low	98.06%	ATR	1.34
Employees	181	Current Ratio	7.40	Sales Q/Q	12.30%	Oper. Margin	-34.60%	RSI (14)	35.64	Volatility	6.19% 5.26%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-498.40%	Profit Margin	-34.80%	Rel Volume	0.61	Prev Close	20.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 06 AMC	Payout	-	Avg Volume	614.05K	Price	20.36
Recom	1.60	SMA20	-14.25%	SMA50	-9.42%	SMA200	10.56%	Volume	378,740	Change	-1.78%

Apr-12-21

Initiated

Piper Sandler

Overweight

$32

Mar-01-21

Initiated

Stifel

Buy

$30

Feb-26-21

Reiterated

H.C. Wainwright

Buy

$21 → $26

Mar-10-20

Initiated

The Benchmark Company

Buy

Jan-17-19

Upgrade

First Analysis Sec

Neutral → Outperform

$12 → $19

May-16-18

Initiated

Stephens

Overweight

$16

Oct-13-17

Reiterated

H.C. Wainwright

Buy

$8 → $8.50

May-31-17

Initiated

Jefferies

Buy

Jan-26-17

Downgrade

First Analysis Sec

Overweight → Equal-Weight

$5.50

Jan-04-17

Upgrade

Ladenburg Thalmann

Neutral → Buy

Jan-06-16

Initiated

H.C. Wainwright

Buy

Apr-22-21 04:05PM	Codexis to Report First Quarter 2021 Financial Results on May 6 GlobeNewswire
Apr-05-21 03:10PM	Codexis Stock Shows Improving Market Leadership; Earns 83 RS Rating Investor's Business Daily
Mar-30-21 02:51AM	Codexis (NASDAQ:CDXS) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +6.96%
Mar-01-21 10:14AM	Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021 Benzinga +6.20%
Feb-25-21 04:55PM	Codexis: Q4 Earnings Insights Benzinga -7.21%
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results GlobeNewswire
02:30PM	Codexis, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 04:05PM	Codexis to Present at Upcoming Virtual Healthcare Conferences GlobeNewswire
Feb-16-21 05:59AM	Codexis (CDXS) is Roubaix Capitals Star Performer During the Q4 of 2020 Insider Monkey
Feb-13-21 02:19AM	Is Now The Time To Look At Buying Codexis, Inc. (NASDAQ:CDXS)? Simply Wall St.
Feb-11-21 04:05PM	Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25 GlobeNewswire
Feb-09-21 04:05PM	Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth GlobeNewswire
Feb-03-21 04:05PM	Codexis Appoints Dr. Esther Martinborough to its Board of Directors GlobeNewswire
Jan-13-21 07:00AM	Codexis Introduces Improved Enzymes to Further Enhance Tate & Lyle's Stevia and Allulose Production GlobeNewswire
Jan-08-21 12:55AM	What Kind Of Investors Own Most Of Codexis, Inc. (NASDAQ:CDXS)? Simply Wall St.
Jan-05-21 07:00AM	Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire
Dec-31-20 07:31PM	Why BlackRock Stock Will Continue to Rock Barrons.com
Dec-30-20 02:50PM	Wednesdays 10 Notable Stocks in Focus Insider Monkey
Dec-14-20 11:39AM	Is CDXS A Good Stock To Buy Now? Insider Monkey +7.35%
Dec-08-20 12:44AM	A Look At The Fair Value Of Codexis, Inc. (NASDAQ:CDXS) Simply Wall St.
Dec-02-20 11:11PM	Codexis Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:25PM	Codexis Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-24-20 05:02PM	Codexis and Casdin Capital Launch SynBio Innovation Accelerator GlobeNewswire
Nov-09-20 07:00AM	Codexis to Participate at Three Virtual Investment Conferences in November GlobeNewswire +6.97%
Nov-07-20 08:38AM	Codexis (NASDAQ:CDXS) Shareholders Have Enjoyed A Whopping 305% Share Price Gain Simply Wall St.
Nov-05-20 08:30PM	Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Codexis Reports Third Quarter 2020 Financial Results GlobeNewswire
02:45PM	Codexis, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 07:00AM	Codexis to Hold Third Quarter 2020 Conference Call on November 5 GlobeNewswire
Sep-08-20 07:00AM	Codexis to Present at Two Virtual Investment Conferences in September GlobeNewswire
Aug-11-20 08:33AM	Codexis Dodges Coronavirus Slowdown in Q2 Motley Fool
Aug-06-20 04:05PM	Codexis Reports Second Quarter 2020 Financial Results GlobeNewswire
07:00AM	Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors GlobeNewswire
Jul-30-20 07:00AM	Codexis to Hold Second Quarter 2020 Conference Call on August 6 GlobeNewswire
Jul-28-20 12:33PM	Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline Zacks
Jun-23-20 07:00AM	Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis GlobeNewswire
Jun-22-20 03:06PM	Hedge Funds Are Selling Codexis, Inc. (CDXS) Insider Monkey
Jun-16-20 04:05PM	Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders GlobeNewswire
Jun-14-20 03:50PM	Edited Transcript of CDXS.OQ earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-01-20 04:05PM	Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets GlobeNewswire
May-27-20 07:00AM	Codexis to Participate in Two Virtual Investment Conferences GlobeNewswire
May-22-20 07:31PM	Should Codexis Investors Prepare for Slower Growth? Motley Fool
May-11-20 07:00AM	Codexis to Present at the UBS Virtual Healthcare Conference GlobeNewswire
06:51AM	H.C. Wainwright Sticks to Their Buy Rating for Codexis Investing.com
May-09-20 01:30AM	Codexis(CDXS) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:05PM	Codexis Reports First Quarter 2020 Financial Results GlobeNewswire
May-06-20 04:05PM	Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader GlobeNewswire
May-05-20 07:00AM	Codexis Expands and Strengthens its Leadership Team with Two Executive Hires GlobeNewswire +5.83%
Apr-30-20 07:00AM	Codexis to Hold First Quarter 2020 Conference Call on May 7 GlobeNewswire
Apr-27-20 12:31PM	Earnings Preview: Codexis (CDXS) Q1 Earnings Expected to Decline Zacks +6.19%
Apr-07-20 08:37AM	Is Codexis, Inc.'s (NASDAQ:CDXS) CEO Pay Justified? Simply Wall St.
Mar-23-20 07:00AM	Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders GlobeNewswire +11.02%
Mar-13-20 01:57PM	Edited Transcript of CDXS earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents +8.41%
Mar-02-20 10:15AM	Company News for Mar 2, 2020 Zacks
Mar-01-20 07:19AM	Analysts Have Been Trimming Their Codexis, Inc. Price Target After Its Latest Report Simply Wall St.
Feb-27-20 06:55PM	Codexis (CDXS) Q4 Earnings and Revenues Lag Estimates Zacks
04:05PM	Codexis Reports 2019 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-25-20 07:00AM	Codexis to Present at Two Investment Conferences in March GlobeNewswire
Feb-20-20 07:00AM	Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27 GlobeNewswire
Jan-31-20 07:52AM	Have Insiders Been Buying Codexis, Inc. (NASDAQ:CDXS) Shares This Year? Simply Wall St.
Jan-13-20 04:05PM	Codexis Attends Opening Ceremony for Portons Fermentation Pilot Lab in Chongqing GlobeNewswire
Jan-10-20 07:00AM	Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement GlobeNewswire
Jan-01-20 09:06AM	We're Not Very Worried About Codexis's (NASDAQ:CDXS) Cash Burn Rate Simply Wall St.
Dec-24-19 07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
Dec-23-19 07:00AM	Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing GlobeNewswire
Dec-16-19 06:10AM	Hedge Funds Are Dumping Codexis, Inc. (CDXS) Insider Monkey
Dec-05-19 04:05PM	Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir GlobeNewswire
Dec-02-19 12:32PM	Codexis (NASDAQ:CDXS) Shareholders Have Enjoyed A Whopping 567% Share Price Gain Simply Wall St.
Nov-16-19 09:39PM	Edited Transcript of CDXS earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-06-19 09:00AM	Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Zacks +9.43%
Nov-05-19 07:55PM	Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates Zacks
04:05PM	Codexis Reports Third Quarter 2019 Financial Results GlobeNewswire
07:00AM	Codexis to Participate in Four Investment Conferences in November GlobeNewswire
Oct-29-19 07:00AM	Codexis to Hold Third Quarter 2019 Conference Call on November 5 GlobeNewswire
Oct-27-19 08:13PM	Is Codexis, Inc. (CDXS) A Good Stock To Buy ? Insider Monkey
Oct-26-19 09:13AM	A Look At The Fair Value Of Codexis, Inc. (NASDAQ:CDXS) Simply Wall St.
Oct-15-19 04:05PM	Codexis Protein Engineering Forum Highlights Progress and Future Direction of the Field GlobeNewswire
Sep-26-19 08:00AM	Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit Business Wire
07:00AM	Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-20-19 06:57AM	Is Codexis, Inc.'s (NASDAQ:CDXS) CEO Pay Justified? Simply Wall St.
Aug-29-19 07:11AM	3 Top Stocks Under $20 Motley Fool
Aug-22-19 11:15PM	Codexis Inc (CDXS) President and CEO John J Nicols Bought $133,000 of Shares GuruFocus.com
Aug-09-19 01:32PM	Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 03:49PM	Codexis Rolls Into Second Half Armed with Cash Motley Fool -16.07%
08:25AM	Codexis(CDXS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 07:35PM	Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:06PM	Codexis Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-30-19 07:00AM	Codexis to Hold Second Quarter 2019 Conference Call on August 6 GlobeNewswire
Jun-27-19 03:01PM	3 Top Stocks Under $20 Motley Fool
Jun-20-19 07:00AM	Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives GlobeNewswire
Jun-10-19 12:06PM	Is Codexis a Buy? Motley Fool
May-30-19 07:00AM	Codexis to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-16-19 09:34AM	Who Has Been Selling Codexis, Inc. (NASDAQ:CDXS) Shares? Simply Wall St.
May-15-19 09:00AM	Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader GlobeNewswire
May-14-19 04:05PM	Codexis to Participate at Three Investment Conferences in May GlobeNewswire
May-10-19 01:51AM	Edited Transcript of CDXS earnings conference call or presentation 6-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 10:07AM	Codexis Bags Novartis as Software Customer, Stays Course in First Quarter Motley Fool
May-07-19 10:57AM	Hedge Funds Have Never Been This Bullish On Codexis, Inc. (CDXS) Insider Monkey -6.55%
03:23AM	Codexis(CDXS) Q1 2019 Earnings Call Transcript Motley Fool
May-06-19 07:25PM	Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates Zacks

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KELLEY BERNARD J	Director	Apr 21	Sale	22.64	2,500	56,608	206,136	Apr 22 04:12 PM
Yang Patrick Y	Director	Apr 05	Sale	24.27	10,000	242,732	83,716	Apr 07 04:48 PM
WOLF DENNIS P	Director	Mar 25	Sale	20.44	10,000	204,351	41,129	Mar 29 04:07 PM
KELLEY BERNARD J	Director	Mar 08	Option Exercise	10.51	20,000	210,200	228,636	Mar 09 04:20 PM
KELLEY BERNARD J	Director	Mar 08	Sale	18.72	20,000	374,350	208,636	Mar 09 04:20 PM
Dorgan Byron L	Director	Jan 21	Option Exercise	10.63	25,000	265,750	187,790	Jan 21 07:29 PM
KELLEY BERNARD J	Director	Jan 21	Sale	24.98	2,500	62,439	208,636	Jan 21 07:30 PM
Dorgan Byron L	Director	Jan 21	Sale	25.17	25,000	629,195	162,790	Jan 21 07:29 PM
Dorgan Byron L	Director	Jan 20	Option Exercise	10.63	25,000	265,750	187,790	Jan 21 07:29 PM
Dorgan Byron L	Director	Jan 20	Sale	26.75	25,000	668,658	162,790	Jan 21 07:29 PM
WOLF DENNIS P	Director	Dec 21	Sale	19.99	10,000	199,874	51,129	Dec 22 04:08 PM
KELLEY BERNARD J	Director	Oct 21	Sale	14.00	2,500	35,007	211,136	Oct 23 04:04 PM
Dorgan Byron L	Director	Oct 09	Option Exercise	10.63	25,000	265,750	187,790	Oct 13 04:04 PM
Dorgan Byron L	Director	Oct 09	Sale	13.54	25,000	338,528	162,790	Oct 13 04:04 PM
Dorgan Byron L	Director	Oct 08	Option Exercise	10.63	25,000	265,750	187,790	Oct 13 04:04 PM
Dorgan Byron L	Director	Oct 08	Sale	13.49	25,000	337,315	162,790	Oct 13 04:04 PM
WOLF DENNIS P	Director	Sep 24	Sale	11.68	10,000	116,845	61,129	Sep 28 04:03 PM
KELLEY BERNARD J	Director	Jul 21	Sale	12.79	2,500	31,965	213,636	Jul 23 04:16 PM
WOLF DENNIS P	Director	Jun 25	Sale	10.97	10,000	109,694	71,129	Jun 26 04:18 PM
BARUCH THOMAS R	Director	Jun 12	Sale	10.61	4,947	52,464	33,093	Jun 16 04:03 PM

open in screener | open in yahoo | open in reuters | open in marketwatch | open in google

publish chart | save to portfolio | create alert

SRPT [NASD]

Sarepta Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-7.07	Insider Own	4.70%	Shs Outstand	78.91M	Perf Week	3.88%
Market Cap	5.85B	Forward P/E	-	EPS next Y	-4.50	Insider Trans	-0.45%	Shs Float	75.12M	Perf Month	-1.57%
Income	-554.10M	PEG	-	EPS next Q	-1.78	Inst Own	89.80%	Short Float	9.67%	Perf Quarter	-21.30%
Sales	540.10M	P/S	10.83	EPS this Y	26.80%	Inst Trans	0.16%	Short Ratio	6.57	Perf Half Y	-47.00%
Book/sh	9.65	P/B	7.54	EPS next Y	34.60%	ROA	-19.10%	Target Price	-	Perf Year	-39.07%
Cash/sh	24.11	P/C	3.02	EPS next 5Y	-	ROE	-57.70%	52W Range	68.04 - 181.83	Perf YTD	-57.32%
Dividend	-	P/FCF	231.25	EPS past 5Y	-6.40%	ROI	-32.20%	52W High	-59.98%	Beta	1.45
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	236.40%	Gross Margin	88.30%	52W Low	6.95%	ATR	2.92
Employees	866	Current Ratio	6.00	Sales Q/Q	45.00%	Oper. Margin	-	RSI (14)	47.33	Volatility	4.76% 3.94%
Optionable	Yes	Debt/Eq	1.30	EPS Q/Q	24.10%	Profit Margin	-	Rel Volume	0.89	Prev Close	74.02
Shortable	Yes	LT Debt/Eq	1.30	Earnings	May 05 AMC	Payout	-	Avg Volume	1.11M	Price	72.77
Recom	2.20	SMA20	1.46%	SMA50	-6.34%	SMA200	-40.59%	Volume	981,643	Change	-1.69%

Apr-26-21

Resumed

Credit Suisse

Neutral

$72

Jan-12-21

Downgrade

Citigroup

Buy → Neutral

$215 → $108

Jan-11-21

Downgrade

UBS

Buy → Neutral

Jan-08-21

Downgrade

Raymond James

Outperform → Mkt Perform

Jan-08-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$95

Jan-08-21

Downgrade

JP Morgan

Overweight → Underweight

$96

Nov-11-20

Initiated

Berenberg

Hold

Oct-28-20

Initiated

UBS

Buy

$212

Aug-25-20

Initiated

Raymond James

Outperform

$200

Aug-20-20

Downgrade

Credit Suisse

Outperform → Neutral

$185 → $167

Mar-31-20

Initiated

Mizuho

Buy

$183

Nov-01-19

Initiated

Guggenheim

Buy

$183

Aug-21-19

Reiterated

Needham

Buy

$196 → $170

Jul-09-19

Reiterated

Morgan Stanley

Overweight

$165 → $220

Jul-01-19

Reiterated

RBC Capital Mkts

Outperform

$188 → $220

Apr-12-19

Initiated

Evercore ISI

Outperform

Mar-11-19

Reiterated

Credit Suisse

Outperform

$189 → $207

Oct-12-18

Initiated

Bernstein

Outperform

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$217

Sep-26-18

Reiterated

RBC Capital Mkts

Outperform

$187 → $200

May-06-21 03:01AM	Sarepta Therapeutics (SRPT) Q1 2021 Earnings Call Transcript Motley Fool
May-05-21 07:15PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments GlobeNewswire
02:45PM	Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 04:30PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-03-21 01:22PM	Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients Benzinga +8.85%
08:50AM	Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 GlobeNewswire
08:02AM	MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders GlobeNewswire
Apr-30-21 06:45PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
04:05PM	Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
06:06AM	3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street Motley Fool
Apr-28-21 12:34PM	Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for Zacks
08:30AM	Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021 GlobeNewswire
Apr-26-21 04:05PM	Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation GlobeNewswire
Apr-07-21 04:53PM	Is SRPT Stock A Buy or Sell? Insider Monkey
Apr-01-21 10:39AM	Is Sarepta Therapeutics Worthy of Redemption? Motley Fool
Mar-25-21 07:47AM	Sarepta Therapeutics' Long-Term Potential Is in Flux Motley Fool
Mar-23-21 08:30AM	Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program GlobeNewswire -5.93%
Mar-19-21 04:24PM	Can Sarepta's 'Remarkable' Gene Therapy Pull Shares Out Of The Dumps? Investor's Business Daily
Mar-18-21 04:31PM	Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration GlobeNewswire
Mar-15-21 08:30AM	Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference GlobeNewswire
Mar-02-21 10:02AM	Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates Zacks
08:57AM	Sarepta Therapeutics Stock Drops on Earnings. Why Analysts Remain Hopeful. Barrons.com
02:01AM	Sarepta Therapeutics (SRPT) Q4 2020 Earnings Call Transcript Motley Fool
Mar-01-21 05:55PM	Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:28PM	Recap: Sarepta Therapeutics Q4 Earnings Benzinga
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments GlobeNewswire
02:30PM	Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-21 07:12PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:16AM	Earnings Preview: Sarepta Therapeutics Benzinga
Feb-25-21 03:48PM	Sarepta stock rises after FDA approves biotech's Duchenne MD treatment MarketWatch
02:10PM	Sarepta Therapeutics Announces FDA Approval of AMONDYS 45 (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 GlobeNewswire
Feb-24-21 04:30PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-22-21 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021 GlobeNewswire
05:48AM	The Sarepta Therapeutics (NASDAQ:SRPT) Share Price Has Soared 543%, Delighting Many Shareholders Simply Wall St.
Feb-16-21 09:11AM	Bluebird Bio Suspends Gene Therapy Trials, Marketing After Cancer Diagnosis Barrons.com
Feb-15-21 09:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT Newsfile
Feb-13-21 03:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT ACCESSWIRE
Feb-11-21 12:37PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT Newsfile
Feb-08-21 07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT ACCESSWIRE
11:11AM	ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Newsfile
Feb-06-21 11:18PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT Newsfile
Feb-04-21 07:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT PR Newswire
04:30PM	Sarepta Therapeutics Announces Winners of the Rare Lessons Lesson Planning Competition GlobeNewswire
Feb-03-21 11:15AM	SRPT Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation ACCESSWIRE
Feb-01-21 05:16PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm PR Newswire
Jan-29-21 08:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-22-21 07:00AM	Pfizer Stock 2021: A Lean, Mean, Covid-Fighting Machine? Investor's Business Daily
Jan-21-21 10:35AM	Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt? Zacks
Jan-15-21 01:20PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
Jan-14-21 12:28PM	The SolarWinds Hack Was Huge. Heres Why JPMorgan Is Defending the Stock. Barrons.com
10:26AM	Sarepta (SRPT) Inks New Gene Editing Research Collaboration Zacks
Jan-13-21 01:00PM	IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
08:30AM	Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics GlobeNewswire
Jan-12-21 01:30PM	Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire
10:17AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
08:57AM	Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session Zacks
06:00AM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Jan-11-21 08:01PM	Sarepta Stock Gets Mixed Reviews From Analysts TipRanks +9.08%
03:11PM	Sarepta Stock Gains as CEO Explains What Went Wrong With Gene-Therapy Trial Barrons.com
02:45PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
12:00PM	SRPT Shareholder Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation ACCESSWIRE
08:11AM	Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs Barrons.com
Jan-10-21 01:00PM	SRPT Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation ACCESSWIRE
07:56AM	Here's Why Sarepta Therapeutics Lost Support on Wall Street Motley Fool
Jan-09-21 07:15PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm ACCESSWIRE
01:15PM	SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT PR Newswire
Jan-08-21 07:23PM	Sarepta Stock Dropped 50% After Gene-Therapy Setback. What to Do Now. Barrons.com -51.29%
06:48PM	SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws PR Newswire
05:16PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
04:30PM	Sarepta Tanks On Likely 2-Year Delay For Muscular Dystrophy Gene Therapy Investor's Business Daily
01:35PM	SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. SRPT Business Wire
01:25PM	Dow Jones Falls As Economy Loses Jobs; Nio Hits New Buy Point, While Tesla Surges On New Model Y Investor's Business Daily
11:57AM	Why Solid Biosciences Stock Is Sinking Today Motley Fool
11:44AM	Is Sarepta Stock Worth Buying After the 50% Plunge? Analyst Weighs In TipRanks
11:38AM	Why Sarepta Therapeutics Stock Is Crashing Today Motley Fool
10:15AM	ROCE Insights For Sarepta Therapeutics Benzinga
09:39AM	Sarepta Craters, Cutting Market Value in Half on Therapy Miss Bloomberg
09:36AM	Sarepta Sinks on Disappointing Gene-Therapy Study Results TheStreet.com
09:08AM	Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate Zacks
08:30AM	Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-07-21 05:13PM	Sarepta stock plunges more than 50% after mixed results from drug study MarketWatch
05:11PM	Sarepta Craters as Gene Therapy Miss Sparks Unease for Peers Bloomberg
04:05PM	Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Jan-06-21 04:15PM	This Small Gene Therapy Stock Is Taking On Giants Regeneron, Roche Investor's Business Daily
Jan-05-21 06:00AM	Get Ready for Health-Care Stocks to Go Wild. How to Play Them. Barrons.com
Jan-04-21 10:32AM	Unusual Options Activity Insight: Sarepta Therapeutics Benzinga
Dec-31-20 06:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-24-20 04:41AM	Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St.
Dec-22-20 12:56PM	4 Biopharma Stock Picks From Analysts for 2021 Barrons.com
Dec-20-20 03:14PM	Is SRPT A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-18-20 02:00PM	Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst Benzinga
Dec-14-20 08:30AM	Sarepta Therapeutics Announces Executive Management Changes GlobeNewswire
Dec-09-20 10:42AM	Sarepta Therapeutics Sees Relative Strength Rating Improve To 74 Investor's Business Daily
Dec-08-20 10:07AM	Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051 Zacks
Dec-07-20 01:57PM	Sarepta Therapeutics Earns Relative Strength Rating Upgrade Investor's Business Daily
08:55AM	Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 GlobeNewswire
Dec-05-20 11:32AM	Sarepta Therapeutics (SRPT) Up 8.9% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-20 04:05PM	Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Nov-30-20 06:05PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BEHRENS M KATHLEEN	Director	Mar 10	Option Exercise	42.30	5,000	211,500	135,517	Mar 10 08:04 PM
BEHRENS M KATHLEEN	Director	Mar 10	Sale	85.76	5,000	428,800	130,517	Mar 10 08:04 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08	Option Exercise	34.92	10,000	349,200	26,518	Mar 10 08:03 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08	Sale	83.51	10,000	835,100	16,518	Mar 10 08:03 PM
Bratica Joseph	Principal Financial Officer	Dec 11	Option Exercise	71.45	1,115	79,667	9,255	Dec 14 08:00 PM
Bratica Joseph	Principal Financial Officer	Dec 11	Sale	165.00	1,115	183,975	8,140	Dec 14 08:00 PM
GRAY MARY ANN	Director	Dec 10	Option Exercise	0.00	967	0	5,710	Dec 10 08:24 PM
Bratica Joseph	Principal Financial Officer	Dec 08	Option Exercise	29.60	1,125	33,300	9,265	Dec 10 08:23 PM
Bratica Joseph	Principal Financial Officer	Dec 08	Sale	160.00	1,125	180,000	8,140	Dec 10 08:23 PM
Wigzell Hans Lennart Rudolf	Director	Aug 10	Option Exercise	34.92	10,000	349,200	23,792	Aug 11 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 10	Sale	159.00	10,000	1,590,044	13,792	Aug 11 08:00 PM
Barry Richard	Director	Aug 07	Sale	158.50	30,000	4,754,972	3,129,140	Aug 07 08:00 PM
Bratica Joseph	Principal Financial Officer	Aug 03	Option Exercise	29.60	1,125	33,300	8,957	Aug 05 08:00 PM
Bratica Joseph	Principal Financial Officer	Aug 03	Sale	155.00	1,125	174,375	7,832	Aug 05 08:00 PM
Mahatme Sandesh	EVP, CFO & CBO	Jul 08	Option Exercise	19.69	3,806	74,941	20,260	Jul 09 08:00 PM
Howton David T	EVP, General Counsel	Jun 22	Option Exercise	25.76	105,122	2,708,440	136,993	Jun 22 09:17 PM
Howton David T	EVP, General Counsel	Jun 22	Sale	170.88	105,122	17,962,831	31,871	Jun 22 09:17 PM
Wigzell Hans Lennart Rudolf	Director	May 20	Option Exercise	10.08	5,000	50,400	18,792	May 22 08:00 PM
Wigzell Hans Lennart Rudolf	Director	May 20	Sale	150.64	5,000	753,210	13,792	May 22 08:00 PM
Barry Richard	Director	May 15	Sale	141.26	30,000	4,237,946	3,159,140	May 15 09:02 PM

open in screener | open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience